Loefflers syndrome differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 35: Line 35:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ELISA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ELISA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CXR
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CXR
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CT Scan
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3
|-
|-
Line 81: Line 81:


eosinophilia
eosinophilia
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |cough, breathlessness, wheezing, fatigue, and fever.
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 88: Line 88:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |40 to 70 percent
| style="background: #F5F5F5; padding: 5px;" |40 to 70 percent
(>3000/microL)
plus elevated IgE levels ( >1000 units/mL)
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Diffuse opacities
* Around 20% of  patients have a normal CXR
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Reticular and small nodular opacities
* Bronchiectasis
* Air trapping
* Calcification
* Mediastinal adenopathy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 140: Line 150:
ELISA is generally positive while stool examination is often negative.
ELISA is generally positive while stool examination is often negative.
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
'''Strongyloides:''' diffuse ground glass opacities
'''Strongyloides:''' diffuse ground glass opacities
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 176: Line 185:
| rowspan="2" |Nonhelminthic infections
| rowspan="2" |Nonhelminthic infections
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 184: Line 194:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Antibody testing may be negative early in the course of disease
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 193: Line 203:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 228: Line 237:
| colspan="2" |Drug- and toxin-induced eosinophilic lung diseases
| colspan="2" |Drug- and toxin-induced eosinophilic lung diseases
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* asymptomatic pulmonary infiltration with eosinophils, chronic cough with or without dyspnea and fever, acute eosinophilic pneumonia, and
* DRESS should be suspected when the patient has a skin eruption, fever, facial edema, enlarged lymph nodes, and a history of initiation of a culprit medication two to six weeks prior to disease onset
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 242: Line 253:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* '''Medications such as:'''
* Nonsteroidal antiinflammatory drugs
* Nonsteroidal antiinflammatory drugs
* Phenytoin
* Phenytoin
* L-tryptophan
* L-tryptophan
* Antibiotics (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin)
* Antibiotics (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin)
* '''Toxins such as:'''
* Aluminum silicate and particulate metals  •Sulfite  •Scorpion stings  •Inhalation of o heroin, crack cocaine, or marijuana  •Inhalation of organic chemicals, dust or smoke, during rubber manufacture, fireworks, firefighting, tobacco smoking  •Abuse of 1,1,1-trichloroethane (Scotchgard)
|-
|-
|
|

Revision as of 16:12, 21 May 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.

Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Physical exam 2 Physical exam 3 Increased Eosinophil count

(High)

Increased Eosinophil count

(Mild to moderate)

ELISA CXR CT Scan Imaging 3
Helminthic

and fungal infection-related

eosinophilic lung diseases

Transpulmonary

passage of larvae (Loffler's syndrome)

Cough

Sputum production

Wheezing

Fever

  • Round or oval opacities (several millimeters to several centimeters)
  • In both lungs
  • Generally present when blood eosinophilia exceeds 10%
  • Migratory
  • May become confluent in perihilar areas
  • Generally clear spontaneously
  • Ascaris lumbricoides
  • Hookworms such as:
  • Ancylostoma duodenale
  • Necator americanus)
  • Strongyloides stercoralis
Tropical

pulmonary

eosinophilia

cough, breathlessness, wheezing, fatigue, and fever. 40 to 70 percent

(>3000/microL)

plus elevated IgE levels ( >1000 units/mL)

  • Diffuse opacities
  • Around 20% of patients have a normal CXR
  • Reticular and small nodular opacities
  • Bronchiectasis
  • Air trapping
  • Calcification
  • Mediastinal adenopathy
  • Wuchereria bancrofti
  • Brugia malayi
Allergic bronchopulmonary aspergillosis *
Heavy

hematogenous

seeding

with

helminths

depends on the organism for example:

periorbital edema, myositis, and eosinophilia (Trichinellosis)

* * Trichinellosis: will be positive 2-8 weeks after infection

Strongyloides:

ELISA is generally positive while stool examination is often negative.

Strongyloides: diffuse ground glass opacities

  • Ascarids and hookworms
  • Trichinellosis
  • Disseminated strongyloidiasis
  • Cutaneous and visceral larva migrans
  • Schistosomiasis
  • Prior treatment with glucocorticoids may be a risk factor.
Pulmonary parenchymal invasion Eosinophilia is prominent in the early stages of disease but minimal with established disease Useful in later infection with Paragonimus
  • Nodular with surrounding areas of ground glass
  • Peripheral
  • Common in the mid- and lower lung zones
Finding eggs in the sputum or bronchoalveolar lavage fluid
  • Helminths such as paragonimiasis
Nonhelminthic infections Coccidioidomycosis Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
  • Antibody testing may be negative early in the course of disease
Mycobacterium tuberculosis
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) *
Drug- and toxin-induced eosinophilic lung diseases
  • asymptomatic pulmonary infiltration with eosinophils, chronic cough with or without dyspnea and fever, acute eosinophilic pneumonia, and
  • DRESS should be suspected when the patient has a skin eruption, fever, facial edema, enlarged lymph nodes, and a history of initiation of a culprit medication two to six weeks prior to disease onset
*
  • Medications such as:
  • Nonsteroidal antiinflammatory drugs
  • Phenytoin
  • L-tryptophan
  • Antibiotics (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin)
  • Toxins such as:
  • Aluminum silicate and particulate metals •Sulfite •Scorpion stings •Inhalation of o heroin, crack cocaine, or marijuana •Inhalation of organic chemicals, dust or smoke, during rubber manufacture, fireworks, firefighting, tobacco smoking •Abuse of 1,1,1-trichloroethane (Scotchgard)
Acute eosinophilic pneumonia
Chronic eosinophilic pneumonia ≥40 percent
Idiopathic acute eosinophilic pneumonia ≥25 percent
Diseases Symptom 1 Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Increased Eosinophil count

(High)

Increased Eosinophil count

(Mild to moderate)

ELISA Imaging 1 Imaging 2 Imaging 3 Histopathology Gold standard Additional findings
Sarcoidosis *
Pulmonary Langerhans cell histiocytosis (Histiocytosis X) *
Idiopathic pulmonary fibrosis <10 percent
Differential Diagnosis 7

References

Template:WH Template:WS